Group One Trading
PMCB icon

Group One Trading’s PharmaCyte Biotech PMCB Stock Holding History

Group One Trading’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-341,700
Closed -$247K – 8490
2025
Q4 		$247K Buy
+341,700
New +$308K ﹤0.01% 4185
2024
Q2 		– Sell
-21,000
Closed -$49.8K – 7320
2024
Q1 		$49.8K Buy
+21,000
New +$45.5K ﹤0.01% 4730
2023
Q4 		– Sell
-5,000
Closed -$10.5K – 8011
2023
Q3 		$10.5K Hold
5,000
– – ﹤0.01% 6314
2023
Q2 		$14.3K Buy
5,000
+4,900
+4,900% +$14.7K ﹤0.01% 6194
2023
Q1 		$291 Sell
100
-14,500
-99% -$42.6K ﹤0.01% 6966
2022
Q4 		$42.6K Buy
14,600
+100
+0.7% +$286 ﹤0.01% 5116
2022
Q3 		$35K Buy
14,500
+11,500
+383% +$29.1K ﹤0.01% 5687
2022
Q2 		$7K Buy
+3,000
New +$6.56K ﹤0.01% 6948
2022
Q1 		– Sell
-23,400
Closed -$59K – 8529
2021
Q4 		$59K Buy
23,400
+900
+4% +$2.48K ﹤0.01% 6193
2021
Q3 		$71K Buy
+22,500
New +$79.1K ﹤0.01% 6248

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Group One Trading's PMCB Position: Q1 2026 in Review

Group One Trading opened a new position in PharmaCyte Biotech (PMCB) in Q1 2026: 1,785 shares worth $1.19K. The stake represents ﹤0.01% of the portfolio and ranks #7186 among its holdings. This is a return to the name: Group One Trading previously reported a position in PMCB as recently as Q2 2023.

Group One Trading first reported a position in PMCB in Q2 2022 and has held it in 5 quarters since. The position peaked at $180K in Q3 2022. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • Group One Trading held 1,785 shares of PharmaCyte Biotech worth $1.19K as of Q1 2026.
  • PharmaCyte Biotech was a new Group One Trading position in Q1 2026.
  • PharmaCyte Biotech made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #7186 holding.
  • Group One Trading first reported a position in PharmaCyte Biotech in Q2 2022 and has held it in 5 quarters since.
  • Group One Trading's PharmaCyte Biotech position peaked at $180K in Q3 2022.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.